相关临床试验
11
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1956
进行中（未招募）
1
9.1%
已完成
7
63.6%
尚未招募
1
9.1%
招募中
2
18.2%
暂无批准数据
- The IMPALA study demonstrates that injectable HIV treatment with Cabotegravir and Rilpivirine administered every two months is non-inferior to standard oral therapy in African patients with adherence challenges. - The 24-month randomized controlled trial conducted across Kenya, Uganda, and South Africa found the injectable regimen to be safe, well-tolerated, and preferred by most HIV patients. - Results offer renewed hope for addressing the global adherence crisis, with only 71% of people living with HIV achieving viral suppression compared to the UNAIDS 95-95-95 target. - The injectable therapy could help accelerate progress toward reducing HIV-related deaths and improving quality of life for people living with HIV in sub-Saharan Africa.
- Kenya has been selected to host the East Africa Regional Centre of Excellence in Bioequivalence Studies and Pharmaceutical Research at the University of Nairobi, marking a significant step toward pharmaceutical self-reliance in the region. - The EAC has secured €12 million to launch Phase III of its Regional Network of Reference Laboratories project, strengthening pandemic prevention capabilities through a One Health approach integrating human, animal, and environmental health strategies. - The three-year initiative (2025-2028) will operationalize a Regional Centre of Excellence for Virology in Uganda, upgrade mobile laboratories, enhance genomic surveillance, and integrate the DRC into the established laboratory network.
